Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Michael B. Ware"'
Autor:
Mark P Rubinstein, Bei Liu, Eric Bartee, Chrystal M Paulos, Jessica E Thaxton, Aubrey S Smith, Hannah M Knochelmann, Megan M Wyatt, Guillermo O Rangel Rivera, Amalia M Rivera-Reyes, Connor J Dwyer, Michael B Ware, Anna C Cole, David M Neskey
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
Externí odkaz:
https://doaj.org/article/21502930ed1b47cda07b50c2dd546d6c
Autor:
Gregory B. Lesinski, Bassel F. El-Rayes, Shishir K. Maithel, Rafi Ahmed, Juan M. Sarmiento, Zhengjia Chen, Chao Zhang, Ganji Purnachandra Nagaraju, Matthew R. Farren, Hannah Komar, Brian M. Olson, Amanda N. Ruggieri, Mohammad Y. Zaidi, Michael B. Ware, Yuchen Zhang
Supplemental Figures S1-S7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::334b97489ab6bc6ce4b453fc89989db7
https://doi.org/10.1158/1535-7163.22521040
https://doi.org/10.1158/1535-7163.22521040
Autor:
Gregory B. Lesinski, Bassel F. El-Rayes, Shishir K. Maithel, Rafi Ahmed, Juan M. Sarmiento, Zhengjia Chen, Chao Zhang, Ganji Purnachandra Nagaraju, Matthew R. Farren, Hannah Komar, Brian M. Olson, Amanda N. Ruggieri, Mohammad Y. Zaidi, Michael B. Ware, Yuchen Zhang
Pancreatic ductal adenocarcinoma (PDAC) has a prominent fibrotic stroma, which is a result of interactions between tumor, immune and pancreatic stellate cells (PSC), or cancer-associated fibroblasts (CAF). Targeting inflammatory pathways present with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::230926bfbd23653fd8c0df4dc849af8a
https://doi.org/10.1158/1535-7163.c.6542881
https://doi.org/10.1158/1535-7163.c.6542881
Autor:
Rafi Ahmed, Chao Zhang, Matthew R. Farren, Ganji Purnachandra Nagaraju, Shishir K. Maithel, Yuchen Zhang, Amanda Ruggieri, Hannah Komar, Michael B. Ware, Gregory B. Lesinski, Zhengjia Chen, Bassel F. El-Rayes, Mohammad Y. Zaidi, Juan M. Sarmiento, Brian Olson
Publikováno v:
Mol Cancer Ther
Pancreatic ductal adenocarcinoma (PDAC) has a prominent fibrotic stroma, which is a result of interactions between tumor, immune and pancreatic stellate cells (PSC), or cancer-associated fibroblasts (CAF). Targeting inflammatory pathways present with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b22c9aff132534590454c674549b102
https://doi.org/10.1158/1535-7163.mct-19-0911
https://doi.org/10.1158/1535-7163.mct-19-0911
Autor:
Aubrey S Smith, Hannah M Knochelmann, Megan M Wyatt, Guillermo O Rangel Rivera, Amalia M Rivera-Reyes, Connor J Dwyer, Michael B Ware, Anna C Cole, David M Neskey, Mark P Rubinstein, Bei Liu, Jessica E Thaxton, Eric Bartee, Chrystal M Paulos
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundAdoptive T cell transfer (ACT) therapy improves outcomes in patients with advanced malignancies, yet many individuals relapse due to the infusion of T cells with poor function or persistence. Toll-like receptor (TLR) agonists can invigorate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e5ec6ad6e0a7e0f7e909ddae39ac8c2
https://jitc.bmj.com/content/10/1/e003078.full
https://jitc.bmj.com/content/10/1/e003078.full
Autor:
Edmund K. Waller, Maria Cardenas, Gregory B. Lesinski, Bassel F. El-Rayes, Jingru Zhu, Mohammad Y. Zaidi, Shuhua Wang, Brian S. Robinson, Michael B. Ware, Susan N. Thomas, Yuan Liu, Tenzin Passang Fnu, Shanmuganathan Chandrakasan, Sruthi Ravindranathan, Jian-Ming Li, Alan B. Frey, Rohan K. Dhamsania, Sanjeev Gumber, Anish Majumdar, Haydn T. Kissick
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundPaucity of T cells in the immune privileged tumor microenvironment (TME) of pancreatic ductal adenocarcinoma (PDAC) is a major reason that PDAC is refractory to immune checkpoint blockade.1 In this study, we show that human PDAC tumors over
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2dc43293c34290c98f6e5f27a54cb322
https://doaj.org/article/ef457d1db40045839ffa75158ef24e6a
https://doaj.org/article/ef457d1db40045839ffa75158ef24e6a
Autor:
Aubrey S. Smith, Michael B. Ware, Bhavana Pavuluri, Guillermo Rangel RIvera, Megan Wyatt, Anna Cole, Chrystal M. Paulos
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundBRAF mutations are highly prevalent in patients with melanoma (50–65%), and mark tumors which are responsive to combination immune checkpoint inhibition (ICI) with nivolumab (αPD-1) and ipilimumab (αCTLA-4). Interestingly, this combinat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::180c4711ed3dbb6bea448a76d5be8eb7
https://doaj.org/article/0c0c1db17cd743c19d89950828552b76
https://doaj.org/article/0c0c1db17cd743c19d89950828552b76
Autor:
Juan M. Sarmiento, Shishir K. Maithel, Cameron Herting, Gregory B. Lesinski, Chrystal M. Paulos, Maggie Phillips, Megan M. Wyatt, Thomas A. Mace, Michael B. Ware, Bassel F. El-Rayes
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundPancreatic ductal adenocarcinoma (PDAC) is refractory to immunotherapy due in part to cellular cross-talk with cancer associated fibroblasts (CAFs). These interactions shape the microenvironment in a manner that is profoundly immunosuppress
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91f9d494f9ebf1da95028119f5aa3b53
https://doaj.org/article/626cf3db491d42baaac75a0a5857e903
https://doaj.org/article/626cf3db491d42baaac75a0a5857e903
Autor:
Deon B. Doxie, Bassel F. El-Rayes, Gregory B. Lesinski, Olatunji B. Alese, Amanda Ruggieri, Cameron Herting, Walid L. Shaib, Mohammad Y. Zaidi, Kavita M. Dhodapkar, Shishir K. Maithel, Mehmet Akce, Christina Wu, Matthew R. Farren, Michael B. Ware, Rafi Ahmed, Yuchen Zhang, Madhav V. Dhodapkar, Juan M. Sarmiento
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Both pancreatic ductal adenocarcinoma (PDAC) and metastatic colorectal cancer (mCRC) have yet to widely benefit from T cell-targeted immunotherapy and have universally poor prognoses. Thus, enhancing the activity of immunotherapy is a high
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cab08cb1d0768ff8f100f797b1a677c
https://doi.org/10.1136/jitc-2020-sitc2020.0330
https://doi.org/10.1136/jitc-2020-sitc2020.0330
Autor:
Michael K. Turgeon, Omar Elnaggar, Tanios Bekaii-Saab, Thomas A. Mace, Mohammad Y. Zaidi, Zheng Che, Chao Zhang, Jennifer Yang, Gregory B. Lesinski, Matthew R. Farren, Zhengjia Chen, Shishir K. Maithel, Michael B. Ware, Bassel F. El-Rayes, Gregory S. Young, Kaitlin Keenan, Amanda Ruggieri, Yiman Li, Alyssa M. Krasinskas
Publikováno v:
British Journal of Cancer
Background BTC is an aggressive disease exacerbated by inflammation and immune suppression. Expansion of immunosuppressive cells occurs in biliary tract cancer (BTC), yet the role of BTC-derived cytokines in this process is unclear. Methods Activated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ba9b85621527423b88dec3b1157dd83
https://pubmed.ncbi.nlm.nih.gov/32747748
https://pubmed.ncbi.nlm.nih.gov/32747748